Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD Jr, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R, Grote L, Peluso T, Dimopoulos M.
Richardson PG, et al. Among authors: oriol a.
Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. Epub 2021 Sep 22.
Eur J Haematol. 2022.
PMID: 34496096
Free PMC article.
Clinical Trial.